Zhi Tong Cai Jing·2025-10-30 04:03Group 1 - The core viewpoint of the news is that 康龙化成 (Crown Bioscience) has shown a mixed financial performance for the first three quarters of 2025, with revenue growth but a decline in net profit [1] - For the first three quarters of 2025, the company reported a revenue of 10.086 billion yuan, an increase of 14.38% year-on-year, while the net profit attributable to shareholders decreased by 19.76% to 1.141 billion yuan [1] - In Q3 2025, the company achieved a revenue of 3.64 billion yuan, reflecting a year-on-year increase of 13.4%, and a net profit of 440 million yuan, which is a significant increase of 42.5% year-on-year [1] - The company signed new orders that grew over 13% year-on-year, with the laboratory services segment and CMC (small molecule CDMO) services segment seeing increases of over 12% and approximately 20%, respectively [1] - Based on new orders and business trends, the company expects a full-year revenue growth of 12%-16% for 2025, an increase from the previous estimate of 10%-15% [1] Group 2 - 康龙化成 announced an agreement to acquire 82.54% of 佰翱得 (Bai Ao De) for a total consideration of approximately 1.346 billion yuan [2] - Following the acquisition, 佰翱得 will become a subsidiary of 康龙化成, which is expected to enhance the company's technical platform and service capabilities in structural biology and complex drug target protein preparation and analysis [2] - The acquisition is anticipated to create good synergy with the company's existing business platform and customer service capabilities [2]